Ipremom
Paterna, Spain
◆ Total Raised
$17.4M
◆ Stage
seed
◆ Location
Paterna, Spain
◆ Founded
2019
◆ Team size
11-50
◆ Links
◆ About Ipremom
early detection of pregnancy complications
◆ What sets it apart
Uses a maternal blood sample plus cfRNA-based predictive models to assess preeclampsia risk in the first trimester, offering one of the earliest non-invasive screening approaches.
◆ Sectors
◆ Business
Modelhardware
CustomerPregnant women, obstetric care providers, and prenatal care clinics/hospitals
◆ Notable
- Developed the MaiRa test, described as the first market test to assess preeclampsia risk from week 9 of pregnancy
- Claims detection of risk from a simple maternal blood sample in very early pregnancy
- Secured a €2.5M EU grant to accelerate development and launch of its preeclampsia test
- Leads the iPregnostic clinical validation study
- Reports published scientific validation and a risk-assessment pipeline aligned with SaMD standards
◆ Backing funds on Raise
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does Ipremom do?
early detection of pregnancy complications
Where is Ipremom based?
Ipremom is based in Paterna, Spain, founded in 2019.
How much has Ipremom raised?
Ipremom has raised $17.4M in tracked funding and is currently at the seed stage.
Who has invested in Ipremom?
Investors in Ipremom include Carlos Simón Foundation and European Union.